Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
April 23, 2024 13:42 ET
|
Novartis Pharma AG
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...
Targeted Oncology™ announces first recipient of 2024 for its Oncology Icons award program
April 23, 2024 10:46 ET
|
Targeted Oncology™
CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
April 23, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...
Radiofrequency Ablation Devices Market to hit USD 10.4 Bn by 2032, says Global Market Insights Inc.
April 22, 2024 04:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, April 22, 2024 (GLOBE NEWSWIRE) -- Radiofrequency Ablation Devices Market Size is estimated to be valued at USD 10.4 billion by the end of 2032. Increasing application scope in...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
April 17, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
April 17, 2024 03:00 ET
|
Sound Bioventures
Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolytics...
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
April 17, 2024 03:00 ET
|
Theolytics
Oxford, UK April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a...
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
April 16, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
April 12, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...